囊性纤维化中铜绿假单胞菌的治疗方法

The Approach to Pseudomonas aeruginosa in Cystic Fibrosis.

作者信息

Talwalkar Jaideep S, Murray Thomas S

机构信息

Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, PO Box 208086, New Haven, CT 06520-8086, USA; Department of Pediatrics, Yale School of Medicine, 333 Cedar Street, PO Box 208084, New Haven, CT 06520-8084, USA.

Department of Medical Sciences, Frank H Netter MD School of Medicine, Quinnipiac University, 275 Mount Carmel Avenue, Hamden, CT 06518, USA; Division of Infectious Diseases and Immunology, Connecticut Children's Medical Center, 282 Washington Street, Suite 2L, Hartford, CT 06106, USA.

出版信息

Clin Chest Med. 2016 Mar;37(1):69-81. doi: 10.1016/j.ccm.2015.10.004.

DOI:10.1016/j.ccm.2015.10.004

PMID:26857769

Abstract

There is a high prevalence of Pseudomonas aeruginosa in patients with cystic fibrosis and clear epidemiologic links between chronic infection and morbidity and mortality exist. Prevention and early identification of infection are critical, and stand to improve with the advent of new vaccines and laboratory methods. Once the organism is identified, a variety of treatment options are available. Aggressive use of antipseudomonal antibiotics is the standard of care for acute pulmonary exacerbations in cystic fibrosis, and providers must take into account specific patient characteristics when making treatment decisions related to antibiotic selection, route and duration of administration, and site of care.

摘要

囊性纤维化患者中铜绿假单胞菌的感染率很高，并且慢性感染与发病率和死亡率之间存在明确的流行病学联系。预防和早期识别感染至关重要，随着新疫苗和实验室方法的出现，情况有望得到改善。一旦确定病原体，就有多种治疗选择。积极使用抗假单胞菌抗生素是囊性纤维化急性肺部加重期的标准治疗方法，医疗服务提供者在做出与抗生素选择、给药途径和持续时间以及护理地点相关的治疗决策时，必须考虑患者的具体特征。